As described during the September 29-30 virtual conference on pancreatic cancer held by the American Association for Cancer Research (AACR), tumor tissue from 10 PDAC patients scheduled for surgery will be examined prior to transplant, and then re-examined 1 year after surgery to see if the bacterial makeup of the patients’ tumor microenvironment has been changed through the transplants. Read more . . .
In the first clinical trial of its kind, a small group of patients with pancreatic ductal adenoma carcinoma (PDAC) will receive fecal microbial transplants (FMT) to test whether this novel approach might alter the disease’s unique tumor microbiome, leaving recalcitrant tumors open to immunotherapy.[/sbuhead]